Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
A police officer will not face prosecution over the death of Rashan Charles.
Ice is likely to cause tricky travel conditions in parts of England after the UK experienced a weekend of freezing temperatures and snow.
Angela Merkel has taken a step towards forming a cross-party coalition and ending months of political deadlock.